NCT07287410 Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
| NCT ID | NCT07287410 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Centro Neurolesi Bonino Pulejo |
| Condition | Dementia |
| Study Type | OBSERVATIONAL |
| Enrollment | 151 participants |
| Start Date | 2025-12 |
| Primary Completion | 2026-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 151 participants in total. It began in 2025-12 with a primary completion date of 2026-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.
Eligibility Criteria
Inclusion Criteria: * Age between 50 and 86 years. * Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI). * Referral to the neuropsychology clinic for initial assessment or clinical monitoring. * Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires. Exclusion Criteria: * Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases). * Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression). * Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments. * Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation. * Presence of terminal medical or oncological conditions or other illnesses significantly interfering with the assessment procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07287410 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 86 Years, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07287410 currently recruiting?
Yes, NCT07287410 is actively recruiting participants. Contact the research team at francesco.corallo@irccsme.it for enrollment information.
Where is the NCT07287410 trial being conducted?
This trial is being conducted at Messina, Italy.
Who is sponsoring the NCT07287410 clinical trial?
NCT07287410 is sponsored by IRCCS Centro Neurolesi Bonino Pulejo. The trial plans to enroll 151 participants.